明星基金经理“过气”了？百亿主动权益基金业绩强势回应！

Group 1 - The A-share market experienced a rebound in the second quarter, with the Shanghai Composite Index briefly surpassing 3600 points, driven by themes such as AI, new consumption, and innovative pharmaceuticals [1] - Major active equity fund managers, who had faced several years of downturn, saw a collective performance recovery in the second quarter, marking a critical moment to validate their investment philosophies [1] Group 2 - Among active equity funds with over 10 billion yuan, the top performer was the China Europe Medical Health A fund, managed by Zhao Lei and Ge Lan, achieving a year-to-date return of 28.07% [2] - The second-best performer, Xingquan He Yi A, managed by Xie Zhiyu and Xie Zhiyu, recorded a return of 24.70%, attributed to a shift in investment focus towards technology and pharmaceutical growth stocks [2][3] - Ruiyuan Growth Value A, managed by Zhu Lin and Fu Pengbo, ranked third with over 20% growth, focusing on electronic, internet technology, precision manufacturing, and pharmaceuticals [4] Group 3 - Ge Lan expressed optimism about the pharmaceutical sector, citing supportive policy environments and the expansion of commercial health insurance as factors that enhance the payment capacity for innovative drugs [3] - Xie Zhiyu's investment strategy included increasing holdings in innovative pharmaceutical companies listed in Hong Kong, which saw significant price increases in the second quarter [3] - Fu Pengbo noted a structural adjustment in his portfolio, increasing exposure to the PCB industry while reducing traditional energy stocks, indicating a proactive approach to market changes [4]